vatalanib has been researched along with Colorectal Neoplasms in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (77.42) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Köhne, CH; Lenz, HJ | 1 |
| Arnold, D; Grothey, AA; Haerting, J; Unverzagt, S; Wagner, AD | 1 |
| Bajetta, E; Berg, W; Chen, BL; Germond, C; Hecht, JR; Jalava, T; Köhne, CH; Laurent, D; Lebwohl, D; Lin, E; Meinhardt, G; Moore, M; Valle, J; Van Cutsem, E | 1 |
| Berg, W; Bodoky, G; Chen, BL; Hainsworth, JD; Hecht, JR; Jäger, E; Jalava, T; Kerr, D; Laurent, D; Lebwohl, D; Lloyd-Salvant, K; Major, P; Meinhardt, G; Pendergrass, K; Trarbach, T; Wolff, RA | 1 |
| Bruzzi, P; Sobrero, AF | 1 |
| Folprecht, G; Gatter, KC; Giatromanolaki, A; Harris, AL; Jalava, T; Koukourakis, MI; Laurent, D; Lebwohl, D; Meinhardt, G; Shi, MM; Sivridis, E; Trarbach, T | 2 |
| Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Rosen, LS | 1 |
| Drevs, J; Dugan, M; Laurent, D; Morgan, B; Steward, WP; Thomas, AL; Unger, C; Vanhoefer, U; Wiedenmann, B | 1 |
| Ellis, LM | 1 |
| Ball, HA; Buchert, M; Cherryman, GR; Drevs, J; Dugan, M; Fuxuis, S; Hennig, J; Henry, A; Horsfield, MA; Jivan, A; Laurent, D; Lee, L; Marmé, D; Mietlowski, W; Morgan, B; Mross, K; O'Byrne, K; Steward, WP; Thomas, AL; Unger, C | 1 |
| Klem, J | 1 |
| Bilenker, JH; Haller, DG | 1 |
| Goldberg, RM; Penland, SK | 1 |
| Drevs, J; Dugan, M; Henry, A; Laurent, D; Lebwohl, D; Lee, L; Marmé, D; Medinger, M; Mross, K; Pinheiro, J; Schmidt-Gersbach, CI; Steward, WP; Thomas, AL; Unger, C; Wood, J; Zirrgiebel, U | 1 |
| Collins, TS; Hurwitz, HI | 1 |
| Tyagi, P | 1 |
| Allegrini, P; Brueggen, J; Cozens, R; Drevs, J; Guenther, C; Horsfield, M; Lebwohl, D; Lee, L; McSheehy, PM; Morgan, B; Schnell, C; Sharma, S; Steward, WP; Wood, J | 1 |
| Soff, G; Zakarija, A | 1 |
| Morse, MA | 1 |
| Higginson, A; Horsfield, MA; Morgan, B; Steward, WP; Thomas, AL; Utting, JF | 1 |
| Eng, C; Shalan, N | 1 |
| Bartel, C; Henry, A; Laurent, D; Masson, E; Poethig, M; Steward, W; Thomas, AL; Trarbach, T; Vanhoefer, U; Wang, J; Wiedenmann, B | 1 |
| Sorscher, SM | 1 |
| Los, M; Roodhart, JM; Voest, EE | 1 |
| Colgan, SM; Major, P; Mukherjee, S | 1 |
| Abbas, F; André, T; de Gramont, A; Louvet, C; Tournigand, C | 1 |
| Casado, E; Cortés, J; Prat, A | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
17 review(s) available for vatalanib and Colorectal Neoplasms
| Article | Year |
|---|---|
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Humans; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2009 |
Anti-angiogenic therapies for metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Humans; Neovascularization, Pathologic; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2009 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Contrast Media; Drug Screening Assays, Antitumor; Gadolinium; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Phthalazines; Pyridines | 2003 |
Future directions with angiogenesis inhibitors in colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Disease Models, Animal; Drug Approval; Forecasting; Humans; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2004 |
Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Phthalazines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Celecoxib; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyrazoles; Pyridines; RNA, Catalytic; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factors | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
Biological therapy update in colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Phthalazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis.
Topics: Colorectal Neoplasms; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; L-Lactate Dehydrogenase; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2007 |
[Anti-angiogenic treatment and colorectal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Hypertension; Intestinal Perforation; Neovascularization, Pathologic; Phthalazines; Pyridines; Thromboembolism; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
New approaches in angiogenic targeting for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
9 trial(s) available for vatalanib and Colorectal Neoplasms
| Article | Year |
|---|---|
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Pyridines | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Phthalazines; Pyridines; RNA, Messenger; Transcriptome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Endothelial Cells; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liv
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Biomarkers; Colorectal Neoplasms; Contrast Media; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Phthalazines; Predictive Value of Tests; Pyridines; Treatment Outcome | 2003 |
Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Phthalazines; Protein Kinase Inhibitors; Pyridines; Treatment Outcome | 2005 |
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with
Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Colorectal Neoplasms; Dogs; Drug Evaluation, Preclinical; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor | 2006 |
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
Topics: Angiogenesis Inhibitors; Area Under Curve; Colorectal Neoplasms; Contrast Media; Drug Monitoring; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Phantoms, Imaging; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results | 2006 |
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phthalazines; Pyridines | 2007 |
5 other study(ies) available for vatalanib and Colorectal Neoplasms
| Article | Year |
|---|---|
Vatalanib in advanced colorectal cancer: two studies with identical results.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Phthalazines; Pyridines; Treatment Outcome | 2011 |
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Lactate Dehydrogenases; Male; Middle Aged; Phthalazines; Prognosis; Pyridines; Treatment Outcome; Tumor Burden | 2011 |
Antiangiogenic therapy: more promise and, yet again, more questions.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Humans; Liver Neoplasms; Neoplasm Metastasis; Phthalazines; Pyridines | 2003 |
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Topics: Aged; Biomarkers; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2005 |